Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients
F Vincenti, C P Larsen, J Alberu, B Bresnahan, V D Garcia, J Kothari, P Lang, E Mancilla Urrea, P Massari, G Mondragon-Ramirez, R Reyes-Acevedo, K Rice, L Rostaing, S Steinberg, J Xing, M Agarwal, M B Harler, B Charpentier, F Vincenti, C P Larsen, J Alberu, B Bresnahan, V D Garcia, J Kothari, P Lang, E Mancilla Urrea, P Massari, G Mondragon-Ramirez, R Reyes-Acevedo, K Rice, L Rostaing, S Steinberg, J Xing, M Agarwal, M B Harler, B Charpentier
Abstract
The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 year, phase III study in adults receiving a kidney transplant from a living or standard criteria deceased donor. Patients were randomized to a more (MI) or less intensive (LI) regimen of belatacept, or cyclosporine. 471/666 patients completed ≥3 years of therapy. A total of 92% (MI), 92% (LI), and 89% (cyclosporine) of patients survived with a functioning graft. The mean calculated GFR (cGFR) was ∼21 mL/min/1.73 m(2) higher in the belatacept groups versus cyclosporine at year 3. From month 3 to month 36, the mean cGFR increased in the belatacept groups by +1.0 mL/min/1.73 m(2) /year (MI) and +1.2 mL/min/1.73 m(2) /year (LI) versus a decline of -2.0 mL/min/1.73 m(2) /year (cyclosporine). One cyclosporine-treated patient experienced acute rejection between year 2 and year 3. There were no new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases after month 18. Belatacept-treated patients maintained a high rate of patient and graft survival that was comparable to cyclosporine-treated patients, despite an early increased occurrence of acute rejection and PTLD.
Trial registration: ClinicalTrials.gov NCT00256750.
©Copyright 2011 The American Society of Transplantation and the American Society of Transplant Surgeons.
Source: PubMed